P56 SURVIVAL BENEFIT OF BIRTAMIMAB IN MAYO STAGE IV AL AMYLOIDOSIS IN THE PHASE 3 VITAL STUDY WAS CONSISTENT ACROSS ALL KEY BASELINE VARIABLES.

Autor:	Gertz, M., Cohen, A., Comenzo, R., Kastritis, E., Landau, H., Libby, E., Liedtke, M., Sanchorawala, V., Schönland, S., Wechalekar, A., Ando, Y., Koh, Y., Zonder, J., Palladini, G., Nie, C., Karp, C., Jin, Y., Conrad, A., Kinney, G., Merlini, G.
Zdroj:	HemaSphere; May2023 Supplement S2, Vol. 7, p41-42, 2p
Databáze:	Complementary Index
Externí odkaz:	Zobrazit plný text záznamu Plný text